Race and genomics in the Veterans Health Administration.

Clinical implementation of genomic medicine is gaining momentum. Since 2003, there has been a 25% yearly increase in the number of genes linked to specific diseases or treatments. Genetic testing is quickly and steadily being incorporated into clinical practice guidelines across a wide range of health indications, including cancer, cardiology, infectious diseases, mental health, and primary care. Within the Veterans Health Administration (VHA), from 2011 through 2013, more than 80 000 veterans underwent at least 1 of 110 different genetic tests. Tests that have high levels of utilization within the VHA include Factor V Leiden gene to identify patients at risk for venous thrombosis, HLA-B*5701 to identify patients at risk for a hypersensitivity reaction to abacavir (a treatment for HIV), IL28B to evaluate potential responsiveness to peginterferon-α-2b treatment for HCV, and several tests to inform risk, prognosis, or treatment for cancer, including BCR-ABL1, FLT3, JAK2, BRAF, BRCA, c-KIT, EGFR, EML4-ALK, KRAS, MLH1, MSH2, MSH6, among others.

[1]  A. Partin,et al.  African American men with very low-risk prostate cancer exhibit adverse oncologic outcomes after radical prostatectomy: should active surveillance still be an option for them? , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  Gary K. Chen,et al.  Genome-wide association study of prostate cancer in men of African ancestry identifies a susceptibility locus at 17q21 , 2011, Nature Genetics.

[3]  Mark G Birchette,et al.  Comparing Genetic Ancestry and Self-Described Race in African Americans Born in the United States and in Africa , 2008, Cancer Epidemiology Biomarkers & Prevention.

[4]  Jacques Fellay,et al.  Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance , 2009, Nature.

[5]  F. Cappuzzo,et al.  Genetic abnormalities of the EGFR pathway in African American Patients with non-small-cell lung cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  Leah E. Mechanic,et al.  Mutations in the Tyrosine Kinase Domain of the Epidermal Growth Factor Receptor in Non–Small Cell Lung Cancer , 2005, Clinical Cancer Research.

[7]  Jane E. Carpenter,et al.  Genome-wide association study identifies 25 known breast cancer susceptibility loci as risk factors for triple-negative breast cancer. , 2014, Carcinogenesis.

[8]  M. Ladanyi,et al.  Frequency of EGFR and KRAS Mutations in Lung Adenocarcinomas in African Americans , 2011, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[9]  M. Khoury,et al.  Utilization of epidermal growth factor receptor (EGFR) testing in the United States: a case study of T3 translational research , 2013, Genetics in Medicine.